Xenetic Biosciences (XBIO) Competitors $3.20 -0.04 (-1.20%) As of 08/1/2025 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIO vs. VYNE, ELEV, CVKD, MBRX, CYCC, CMMB, RLMD, FNCH, BCAB, and ATNFShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include VYNE Therapeutics (VYNE), Elevation Oncology (ELEV), Cadrenal Therapeutics (CVKD), Moleculin Biotech (MBRX), Cyclacel Pharmaceuticals (CYCC), Chemomab Therapeutics (CMMB), Relmada Therapeutics (RLMD), Finch Therapeutics Group (FNCH), BioAtla (BCAB), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Xenetic Biosciences vs. Its Competitors VYNE Therapeutics Elevation Oncology Cadrenal Therapeutics Moleculin Biotech Cyclacel Pharmaceuticals Chemomab Therapeutics Relmada Therapeutics Finch Therapeutics Group BioAtla 180 Life Sciences Xenetic Biosciences (NASDAQ:XBIO) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Is XBIO or VYNE more profitable? Xenetic Biosciences has a net margin of -142.10% compared to VYNE Therapeutics' net margin of -6,974.55%. Xenetic Biosciences' return on equity of -57.31% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xenetic Biosciences-142.10% -57.31% -49.30% VYNE Therapeutics -6,974.55%-71.89%-58.94% Which has better earnings & valuation, XBIO or VYNE? Xenetic Biosciences has higher revenue and earnings than VYNE Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenetic Biosciences$2.50M1.97-$3.96M-$2.38-1.34VYNE Therapeutics$500K10.74-$39.83M-$0.99-0.36 Does the media prefer XBIO or VYNE? In the previous week, VYNE Therapeutics had 13 more articles in the media than Xenetic Biosciences. MarketBeat recorded 14 mentions for VYNE Therapeutics and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 0.15 beat VYNE Therapeutics' score of -0.55 indicating that Xenetic Biosciences is being referred to more favorably in the media. Company Overall Sentiment Xenetic Biosciences Neutral VYNE Therapeutics Negative Do insiders and institutionals have more ownership in XBIO or VYNE? 15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 14.7% of Xenetic Biosciences shares are owned by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, XBIO or VYNE? Xenetic Biosciences has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Do analysts rate XBIO or VYNE? VYNE Therapeutics has a consensus target price of $6.25, suggesting a potential upside of 1,671.04%. Given VYNE Therapeutics' higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00VYNE Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryXenetic Biosciences beats VYNE Therapeutics on 8 of the 14 factors compared between the two stocks. Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5M$2.46B$5.48B$9.52BDividend YieldN/A1.81%4.73%4.08%P/E Ratio-1.348.9728.6723.80Price / Sales1.97437.63373.5466.64Price / CashN/A157.7635.4557.96Price / Book0.824.838.275.55Net Income-$3.96M$31.62M$3.24B$259.03M7 Day Performance-11.21%-5.28%-3.69%-4.59%1 Month Performance-18.76%4.38%4.33%4.46%1 Year Performance-20.17%-2.49%25.95%18.03% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences1.042 of 5 stars$3.20-1.2%N/A-24.7%$5M$2.50M-1.344Short Interest ↑VYNEVYNE Therapeutics2.5343 of 5 stars$1.44-0.7%$6.25+334.0%-80.6%$21.90M$605K-1.4530Trending NewsAnalyst DowngradeELEVElevation Oncology2.7444 of 5 stars$0.37flat$3.39+827.6%N/A$21.62MN/A-0.4540Upcoming EarningsCVKDCadrenal Therapeutics2.1558 of 5 stars$10.95-5.4%$32.00+192.2%N/A$21.57MN/A-1.184Upcoming EarningsMBRXMoleculin Biotech2.8807 of 5 stars$0.71+28.7%$4.00+465.0%-70.7%$21.39MN/A0.0020News CoverageUpcoming EarningsShort Interest ↑Gap DownCYCCCyclacel Pharmaceuticals0.1891 of 5 stars$13.27-13.8%N/A-97.6%$20.96M$40K-0.0214Short Interest ↑Gap DownCMMBChemomab Therapeutics2.9335 of 5 stars$1.10+0.8%$8.50+673.4%-11.6%$20.72MN/A-1.4520Gap UpRLMDRelmada Therapeutics4.4511 of 5 stars$0.62-3.5%$5.00+709.1%-84.0%$20.51MN/A-0.2510News CoverageUpcoming EarningsFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+556.3%$20.08MN/A-1.42190BCABBioAtla2.0695 of 5 stars$0.34-3.1%$5.00+1,357.7%-81.1%$20.04M$11M-0.2860Upcoming EarningsATNF180 Life Sciences0.6223 of 5 stars$3.32+14.0%N/A+68.6%$20.03MN/A-0.227News CoverageAnalyst ForecastGap DownHigh Trading Volume Related Companies and Tools Related Companies VYNE Competitors ELEV Competitors CVKD Competitors MBRX Competitors CYCC Competitors CMMB Competitors RLMD Competitors FNCH Competitors BCAB Competitors ATNF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XBIO Stock Alerts